


## IN THE CLAIMS

21. (Currently Amended) Monocyclic compounds of formula (I)

wherein:



- 15  $X_1, X_2, X_3, X_4$  are the same or different, and are selected from the group consisting of  $-\text{CONR}-$ ,  $-\text{NRCO}-$ ,  $-\text{CH}_2\text{NR}-$ , and  $-\text{NRCH}_2-$  where R is selected from the group consisting of H,  $\text{C}_{1-3}$  alkyl, and benzyl;
- f and m are the same or different, and is are a number selected from the group consisting of 0, 1 and 2;
- 20  $R_1$  and  $R_2$ , are the same or different, and represent:
- $-(\text{CH}_2)_r \text{Ar}$  where r is 0, 1 or 2 and Ar is an aromatic group selected from the group consisting of benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, benzoimidazole, optionally substituted with up to 2 substituents selected from the group consisting of  $\text{C}_{1-3}$  alkyl,  $\text{C}_{1-3}$  haloalkyl,  $\text{C}_{1-3}$  alkyloxy,  $\text{C}_{2-4}$  amino-alkyloxy,
- 25 halogens, OH,  $\text{NH}_2$ , CN, and  $\text{NR}_6\text{R}_7$ , where  $\text{R}_6$  and  $\text{R}_7$ , same or different, are H or  $\text{C}_{1-3}$  alkyl,
- $R_3$  is  $-(\text{CH}_2)_r \text{Ar}_1$  where r is 0, 1 or 2 and  $\text{Ar}_1$  is an aromatic group selected from the group consisting of benzene, naphthalene, thiophene, benzothiophene, pyridine, quinoline, indole, furan, benzofuran, thiazole, benzothiazole, imidazole, and benzimidazole,

- optionally substituted with up to 2 groups selected from the group consisting of C<sub>1-3</sub> alkyl, C<sub>1-3</sub> haloalkyl, C<sub>1-3</sub> alkyloxy, amino-alkyloxy, halogens, OH, NH<sub>2</sub>, and NR<sub>6</sub>R<sub>7</sub>, where R<sub>6</sub> and R<sub>7</sub>, same or different, are H or C<sub>1-3</sub> alkyl,
- R<sub>4</sub> is ~~NR<sub>8</sub>R<sub>9</sub>~~; -N(R<sub>11</sub>)CO(CH<sub>2</sub>)<sub>h</sub> R<sub>12</sub>; or -COR<sub>13</sub> where R<sub>8</sub> is H or C<sub>1-3</sub> alkyl; h is 0, 1, 2 or 3; and
- 5 R<sub>9</sub> is selected from the group consisting of methanesulfonyl, tosyl, tetrahydropyranyl, tetrahydrothiopyranyl optionally mono or di-substituted by oxygen on the S atom, piperidyl, optionally substituted on the N-atom by a C<sub>1-3</sub> alkyl, C<sub>1-3</sub> acyl, aminosulfonyl, or methanesulfonyl; or a group ~~(CH<sub>2</sub>)<sub>g</sub> R<sub>10</sub>~~ where g is 1, 2, or 3 and R<sub>10</sub> is selected from the group consisting of morpholine, furan and CN;
- 10 or R<sub>8</sub> and R<sub>9</sub> together with the N atom to which they are linked form a piperazine optionally substituted at the other N atom ~~substituted~~ by a C<sub>1-3</sub> alkyl, C<sub>1-3</sub> acyl or methanesulfonyl; -N(R<sub>11</sub>)CO(CH<sub>2</sub>)<sub>h</sub> R<sub>12</sub> where R<sub>11</sub> is H or C<sub>1-3</sub> alkyl; h is 0, 1, 2 or 3; and R<sub>12</sub> is selected from the group consisting of morpholine, pyrrolidine optionally substituted with a hydroxy or hydroxymethyl, piperidine optionally substituted with a 4-hydroxy ~~or~~ 4-carboxyamido ~~or 4-aminosulfonyl group~~,
- 15 piperazine optionally substituted on the N-atom by 4-aminosulfonyl, C<sub>1-3</sub> alkyl, triazole, tetrazole, 5-mercapto-tetrazole, furan, thiophene, thiomorpholine, optionally mono or di-oxygenated on the S-atom, and ~~amino-cyclohexane~~ cyclohexan-1-yl-amino optionally substituted by a hydroxy group; -COR<sub>13</sub> wherein R<sub>13</sub> is a member selected from the group consisting of morpholine and piperazine optionally substituted by a C<sub>2-6</sub> alkyl containing one or more hydroxy groups;
- 20 their enantiomers and mixtures thereof, their diastereoisomers, and their pharmaceutically acceptable salts.

22. (Currently Amended)

Compound according to Claim 21 wherein:

f is 1

m is 0

X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub>, are the same or different and are a member selected from the group consisting of -CONR- and -NRCO-,

5 where R is H or methyl,

R<sub>1</sub> and R<sub>2</sub> are the same or different, are:

-CH<sub>2</sub>Ar wherein Ar is an aromatic group selected from the group consisting of benzene, pyridine, indole, optionally substituted with up to two substituents selected from the group consisting of C<sub>1-3</sub> alkyl, C<sub>1-3</sub> haloalkyl, C<sub>1-3</sub> alkyloxy, C<sub>2-4</sub> amino alkyloxy, halogens, OH, NH<sub>2</sub>, CN, and NR<sub>6</sub>R<sub>7</sub>,  
10 where R<sub>6</sub> and R<sub>7</sub>, same or different, and are H or C<sub>1-3</sub> alkyl;

R<sub>3</sub> is -CH<sub>2</sub>Ar<sub>1</sub> wherein Ar<sub>1</sub> is an aromatic group selected from the group consisting of alpha naphthyl, beta naphthyl, phenyl, phenyl substituted with up to two substituents selected from the group consisting of C<sub>1-3</sub> alkyl, C<sub>1-3</sub> haloalkyl, C<sub>1-3</sub> alkyloxy, halogens, OH, and NH<sub>2</sub>.

23. (Currently Amended) Compounds according to Claim 22 wherein:

15 - X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, X<sub>4</sub> are -CONH-,

- R<sub>1</sub> is indol-3-yl-methyl

- R<sub>2</sub> is phenyl-methyl optionally substituted with up to two substituents selected from the group consisting of chlorine, fluorine, CF<sub>3</sub>, OH and CN; <sub>1</sub> or ~~are~~ is selected from the group consisting of 3-pyridyl-methyl and 4-pyridyl-methyl;

20 - R<sub>3</sub> is benzyl.

24. (Previously Added) Compounds according to claim 23 wherein:

R<sub>4</sub> is a group NR<sub>8</sub>R<sub>9</sub> wherein:

25 R<sub>8</sub> is H or methyl;

R<sub>9</sub> selected from the group consisting of 4-tetrahydropyranyl, 4-tetrahydrothiopyranyl, 1-oxo-tetrahydrothiopyran-4-yl, 1,1-dioxo-tetrahydrothiopyran-4-yl, N-methyl-4-piperidinyl, N-methanesulfonyl-4-piperidinyl, and N-aminosulfonyl-4-piperidinyl,

or R<sub>8</sub> and R<sub>9</sub> together with the N atom to which they are linked represent N-methyl-piperazinyl,

5 N-acetyl-piperazinyl or N-methanesulfonyl-piperazinyl.

25. (Previously Amended) Compounds according to Claim 24 represented by:

- i) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- 10 ii) cyclo{Suc[1-(S)-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- iii) cyclo{Suc[1-(R)-(1-methyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- iv) cyclo{Suc[1-(R)-(4-tetrahydrothiopyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- v) cyclo{Suc[1-(R)-(1-oxo-tetrahydrothiopyran-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- 15 vi) cyclo{Suc[1-(R)-(1,1-dioxo-tetrahydrothiopyran-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- vii) cyclo{Suc[1-(R)-N-methyl-N-(4-tetrahydropyranyl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- viii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Tyr-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- 20 ix) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-F)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- x) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(3,5-F)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- xi) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-CN)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}
- 25 xii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Phe(4-CF<sub>3</sub>)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

-CH<sub>2</sub>NH}}}

xiii) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(4-pyridyl)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)

-CH<sub>2</sub>NH}}}

xiv) cyclo{Suc[1-(R)-(4-tetrahydropyranyl)amino]-Trp-Ala(3-pyridyl)-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)

5 -CH<sub>2</sub>NH}}}

xv) cyclo{Suc[1-(R)-(1-methylsulfonyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)

-CH<sub>2</sub>NH}}}

xvi) cyclo{Suc[1-(R)-(1-aminosulfonyl-piperidin-4-yl)amino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)

-CH<sub>2</sub>NH}}}

10 xvii) cyclo{Suc[1-(R)-4-methyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH}}}

xviii) cyclo{Suc[1-(R)-4-acetyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH}} or

xix) cyclo{Suc[1-(R)-4-methylsulfonyl-piperazin-1-yl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH}}.

15

26. (Previously Amended) Compounds according to Claim 23 wherein:

R<sub>4</sub> represents a group NR<sub>8</sub>R<sub>9</sub>, where R<sub>8</sub> is H and R<sub>9</sub> is methanesulfonyl, tosyl or a group

-(CH<sub>2</sub>)<sub>g</sub>R<sub>10</sub>, wherein g is 1 or 2 and R<sub>10</sub> is morpholine, furan, or CN.

20

27. (Previously Amended) Compounds according to claim 26 represented by:

xx) cyclo{Suc[1-(S)-methylsulfonylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH}}}

xxi) cyclo{Suc[1-(R)-methylsulfonylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH}}}

xxii) cyclo{Suc[1-(S)-(4-methylphenyl)sulfonylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH}}}

xxiii) cyclo{Suc[1-(R)-(4-methylphenyl)sulfonylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH}}}

25

xxiv) cyclo{Suc[1-(S)-2-(4-morpholino)ethylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH}}}

xxv) cyclo{Suc[1-(R)-2-(4-morpholino)ethylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xxvi) cyclo{Suc[1-(R)-2-(2-furyl)methylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]} or

xxvii) cyclo{Suc[1-(R)-2-(2-cyanomethylamino)-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}.

5

28. (Previously Added) Compounds according to claim 23 wherein:

R<sub>4</sub> is a group -N(R<sub>11</sub>)CO(CH<sub>2</sub>)<sub>h</sub>-R<sub>12</sub> wherein R<sub>11</sub> is H, h is 0 or 1, and R<sub>12</sub> is selected from the group consisting of 1-tetrazolyl, 5-mercapto-tetrazol-1-yl, 1-triazolyl, furanyl, thiophenyl, morpholine, 4-  
10 hydroxy-piperidine, 4-carboxyamido-piperidine, 3-hydroxy-pyrrolidine, 2-hydroxymethylpyrrolidine, 4-methyl-piperazine, 4-aminosulfonyl-piperazine, 1-oxo-thiomorpholine, and 4-hydroxy-cyclohexan-1-yl-amino.

29. (Previously Added) Compounds according to Claim 28 represented by:

15 xxviii) cyclo{Suc[1-(R)-2-(4-morpholino)acetylaminol-1-yl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xxix) cyclo{Suc[1-(S)-2-(4-morpholino)acetylaminol-1-yl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xxx) cyclo{Suc[1-(S)-2-(tetrazol-1-yl)acetylaminol-1-yl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xxxi) cyclo{Suc[1-(R)-2-(tetrazol-1-yl)acetylaminol-1-yl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

20 xxxii) cyclo{Suc[1-(S)-2-(5-mercapto-tetrazol-1-yl)acetylaminol-1-yl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xxxiii) cyclo{Suc[1-(R)-2-([1,2,4]triazol-1-yl)acetylaminol-1-yl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xxxiv) cyclo{Suc[1-(R)-2-(2-furyl)carbonylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

25 xxxv) cyclo{Suc[1-(R)-2-(thiophen-3-yl)acetylaminol-1-yl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xxxvi) cyclo{Suc[1-(R)-2-(4-morpholino)carbonylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

xxxvii) cyclo{Suc[1-(R)-2-(4-hydroxy-piperidin-1-yl)acetylaminol-1-yl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}

- C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}}
- xxxviii) cyclo{Suc[1-(R)-2-(4-aminocarbonyl-piperidin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}}
- xxxix) cyclo{Suc[1-(R)-2-(3-hydroxy-pyrrolidin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}}
- 5      -C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}}
- xl) cyclo{Suc[1-(R)-2-(2-(S)-hydroxymethyl-pyrrolidin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}}
- xli) cyclo{Suc[1-(R)-2-(4-methyl-piperazin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}}
- 10    xlii) cyclo{Suc[1-(R)-2-(4-methyl-piperazin-1-yl)carbonylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}}
- xliii) cyclo{Suc[1-(R)-2-(4-aminosulfonyl-piperazin-1-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}}
- xliv) cyclo{Suc[1-(R)-2-(1-oxo-thiomorpholin-4-yl)acetylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}}
- 15    -CH<sub>2</sub>NH]}} or
- xliv) cyclo{Suc[1-(R)-2-(*trans*-4-hydroxy-cyclohexan-1-yl-amino)acetylamino]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}}.
- 20                      30.      (Previously Amended)              Compounds according to Claim 23 wherein:
- R<sub>4</sub> represents a group COR<sub>13</sub> wherein R<sub>13</sub> is morpholine.
31.      (Previously Amended)              Compounds according to claim 30 represented by:
- xlvi) cyclo{Suc[1-(4-morpholino)carbonyl]-Trp-Phe-[(R)-NH-CH(CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>)-CH<sub>2</sub>NH]}}.
- 25

32. (Previously Added) Pharmaceutical compositions containing as active principle compounds of general formula (I) according to Claim 21 in combination with pharmaceutically acceptable carriers or excipients.

5 33. (Previously Added) A method for the treatment of the bronchospastic component of asthma, cough, pulmonary irritation, intestinal spasms or local spasms of bladder, ureters during cystitis, kidney infections and colics wherein amounts of 0.1 to 10mg/kg body weight of an active principle represented by compounds of formula (I) according to Claim 21 are administered to the patient.